These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12324551)

  • 1. Treating sepsis.
    Wenzel RP
    N Engl J Med; 2002 Sep; 347(13):966-7. PubMed ID: 12324551
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks and benefits of activated protein C treatment for severe sepsis.
    Warren HS; Suffredini AF; Eichacker PQ; Munford RS
    N Engl J Med; 2002 Sep; 347(13):1027-30. PubMed ID: 12324562
    [No Abstract]   [Full Text] [Related]  

  • 3. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 4. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 5. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 6. Criteria for use of drotrecogin alfa.
    Jacobi J
    Am J Health Syst Pharm; 2004 Jan; 61(2):203-4; author reply 204-5. PubMed ID: 14750407
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing the use of activated protein C in the treatment of severe sepsis.
    Siegel JP
    N Engl J Med; 2002 Sep; 347(13):1030-4. PubMed ID: 12324563
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of sepsis.
    Mackenzie AF; Bartelink AK
    N Engl J Med; 2007 Mar; 356(11):1179; author reply 1181-2. PubMed ID: 17361493
    [No Abstract]   [Full Text] [Related]  

  • 9. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise.
    Carlet J
    Crit Care Med; 2006 Feb; 34(2):525-9. PubMed ID: 16424736
    [No Abstract]   [Full Text] [Related]  

  • 10. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 11. Severe sepsis and therapy with activated protein C.
    Parrillo JE
    N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486
    [No Abstract]   [Full Text] [Related]  

  • 12. Recombinant human activated protein C sentenced to the death of a thousand cuts?
    O'Brien JM
    Crit Care Med; 2007 Jun; 35(6):1609-10. PubMed ID: 17522532
    [No Abstract]   [Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
    Friedrich JO; Adhikari NK; Meade MO
    Crit Care; 2006; 10(6):427. PubMed ID: 17214908
    [No Abstract]   [Full Text] [Related]  

  • 14. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Rustige J
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698; author reply 1699-70. PubMed ID: 15273923
    [No Abstract]   [Full Text] [Related]  

  • 15. Activated protein C for sepsis.
    Mackenzie A
    N Engl J Med; 2010 Mar; 362(12):1150-1; author reply 1151. PubMed ID: 20335597
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of sepsis therapies on health-related quality of life.
    Erickson SE; Martin GS
    Crit Care; 2008; 12(1):109. PubMed ID: 18254930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
    Mitka M
    JAMA; 2011 Dec; 306(22):2439-40. PubMed ID: 22166598
    [No Abstract]   [Full Text] [Related]  

  • 18. New mode of intervention in sepsis treatment.
    Foubister V
    Drug Discov Today; 2003 Jul; 8(14):610-2. PubMed ID: 12867140
    [No Abstract]   [Full Text] [Related]  

  • 19. Xigris: reducing mortality in adult patients with severe sepsis.
    Larson AM
    Urol Nurs; 2002 Jun; 22(3):200-1. PubMed ID: 12087796
    [No Abstract]   [Full Text] [Related]  

  • 20. The efficacy of drotrecogin alfa depends on severity of illness.
    Deans KJ; Minneci PC; Eichacker PQ; Natanson C
    Crit Care Med; 2004 Nov; 32(11):2347. PubMed ID: 15640655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.